Tazemetostat, a selective inhibitor of EZH2, can effectively block H3K27 methylation and inhibit mutant lymphoma cells.323 The phase 1 part of a phase 1/2 study (NCT01897571) of tazemetostat in relapsed or refractory B-NHLs was completed and demonstrated acceptable safety and potential antitumor activity (ORR 38% and CR 14%).324 Additionally, phase 1 studies are assessing the novel EZH2 inhibitors SHR2554 and PF-06821497 in lymphoma (NCT03603951 and NCT03460977). The gene discussed is EZH2; the disease is lymphoma.